GlassScriptPhysician profile
Ami P Patel
NPI 1396286662
$3,783.63
in general payments reported to CMS, 2019-2025
26 companies · $995 in 2025
The $995 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $218 · 2021: $653 · 2022: $239 · 2023: $560 · 2024: $1,120 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $21.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.30 |
| Education | $21.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,059.81 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $720.40 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.69 | 2021-2025 | Xifaxan, Plenvu |
| Qol Medical, LLC | $214.15 | 2023-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $202.84 | 2022-2024 | |
| Gilead Sciences, INC. | $189.96 | 2020-2025 | |
| Celgene Corporation | $168.40 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $94.17 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $80.35 | 2024-2025 | Axios, Watchman Access System |
| Phathom Pharmaceuticals, INC. | $79.28 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $62.48 | 2023-2024 | Ocaliva |
| Janssen Biotech, INC. | $51.29 | 2025 | Tremfya |
| Celltrion USA INC. | $42.93 | 2024 | Zymfentra |
| Exact Sciences Corporation | $39.74 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $35.72 | 2024 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $35.65 | 2024 | Resmetirom |
| Caris Mpi, INC. | $34.95 | 2025 | Mi Cancer Seek |
| Capsovision, INC. | $34.60 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $33.21 | 2021 | |
| Alexion Pharmaceuticals, INC. | $30.11 | 2024 | Ultomiris |
| Genzyme Corporation | $27.68 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.97 | 2025 | Givlaari |
| Endogastric Solutions, INC | $25.92 | 2024 | Esophyx |
| Ipsen Biopharmaceuticals, INC | $25.78 | 2025 | Bylvay |
| Echosens North America, INC. | $24.36 | 2024 | Fibroscan |
| Braintree Laboratories, INC. | $15.48 | 2025 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.